Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases
Toxicology studies are an essential part of drug development as they help to evaluate the potential safety and toxicity of a drug candidate before it is tested on humans.
- Toxicology studies are an essential part of drug development as they help to evaluate the potential safety and toxicity of a drug candidate before it is tested on humans.
- There is a real need for skin disease drugs that offer high efficacy and a low risk of adverse effects with long-term use.
- For conditions like AD, an inflammatory skin disease that affects up to 25% of babies and young children, there is a need for safer treatment options.
- DB-007-4 is a topical multi-disease treatment that targets important pathways that play a vital role in the development of inflammatory skin diseases while being well-tolerated by skin.